Medtronic Appoints Mike Marinaro as President

The company veteran will now oversee global commercial operations and Greater China in addition to his current duties.

Updated on Oct. 19, 2026 in People

Medtronic Appoints Mike Marinaro as President

Live Poll

Do you trust that large medical device companies are managed with effective, stable leadership?

Medtronic has named Mike Marinaro as company president, effective October 14, 2026. Marinaro will maintain his existing responsibilities for the Medical Surgical portfolio and the Americas while expanding his oversight to include Greater China.

Why it matters

The leadership change aims to foster stronger enterprise alignment across global markets as the company continues to manage its position as the world's largest medical device manufacturer.

The appointment follows an official SEC Form 8-K filing on October 19, 2026. This move consolidates regional oversight for the company, which maintains its primary operational base in Fridley, Minnesota.

The players

Mike Marinaro

He is the newly appointed president of Medtronic who previously led the company's Medical Surgical portfolio.

Medtronic

Headquartered in Ireland with key operations in Fridley, Minnesota, it is the largest medical device company in the world.

The details

Marinaro brings a long history to the role, having joined the company in 2000 and served as executive vice president and president of the Medical Surgical portfolio since 2024. The firm also stated it plans to launch a transradial catheter for renal denervation later in the current fiscal year.

Mike Marinaro joined Medtronic in 2000.
Marinaro became president of the surgical robotics program in 2022.
Marinaro began serving as EVP and president of the Medical Surgical portfolio in 2024.
Marinaro officially became president of Medtronic on October 14, 2026.
Medtronic filed an SEC Form 8-K regarding the leadership change on October 19, 2026.

Market Landscape

This leadership transition follows the ongoing enterprise-wide operational alignment strategy to improve global coordination. The move positions the company to better integrate its international business units as it competes against other global medical device leaders.

The transition is primarily an internal management shift and does not immediately change consumer pricing or product availability for patients. Customers should look for the upcoming launch of a new transradial catheter for renal denervation later in the fiscal year.

The takeaway

Medtronic continues to refine its global management structure to unify its diverse medical device portfolios. The focus remains on leveraging long-term veteran leadership to drive commercial results across major international territories.